BioSpace News Archive

Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology, and rare genetic diseases announced today that members of its senior management team will present at the Jefferies Next Generation IBD Therapeutics Summit.

Two executives from CorVel Corporation (NASDAQ: CRVL), a national provider of risk management solutions, will speak on the future of telehealth, proactive approaches to stress management, and key takeaways from the COVID-19 pandemic at the 2021 National Workers Compensation and Disability Conference in Las Vegas on Oct. 20-21, 2021.

Clearside Biomedical, Inc., a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced that multiple presentations were given at the American Society of Retina Specialists Annual Meeting and at the OIS Retina Summit at ASRS, which took place October 7 - 12, 2021 in San Antonio, TX.

Algernon Pharmaceuticals Inc. is pleased to announce that it has filed a scientific advice meeting request with the United Kingdom (“UK”) Medicines and Healthcare Products Regulatory Agency (“MHRA”) for a Phase 1/2a stroke study with AP-188

Orchard Therapeutics today announced the acceptance of nine abstracts at the upcoming European Society of Gene & Cell Therapy Congress (ESGCT) taking place virtually from October 19-22.

symplr ® announced today that it has completed its acquisition of Halo Health. Terms of the transaction were not disclosed.

Oxurion NV, a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascular retinal disorders, announces that the first patient has been dosed in its Phase 2 clinical study evaluating THR-687 in patients with Diabetic Macular Edema .

Paris, France, 13.10.2021 – 07:00 CET– Pixium Vision SA, a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces positive long-term data from patients implanted with PRIMA, a state-of-the-art implantable chip.

ObsEva SA, a biopharmaceutical company dedicated to improving women’s reproductive health announced a strategic relationship with Syneos Health®, the only fully integrated biopharmaceutical solutions organization, to commercialize linzagolix.

Genentech, a member of the Roche Group, announced new long-term data that reinforce the benefit of early initiation and ongoing treatment of Ocrevus® on disability progression in relapsing multiple sclerosis and primary progressive MS, as well as safety outcomes for an analysis of a shorter two-hour infusion in minority populations.